naturalX to invest in startups addressing preventive health areas including sleep, gut health and longevity.
European investment fund naturalX Health Ventures has launched a €100 million fund focused on advancing consumer health in the region – with the goal of driving a shift from the traditional reactive approach to healthcare towards “proactive health management.” The firm claims it is the first specialized investment fund in Europe to focus exclusively on consumer health.
The healthcare landscape is evolving, with consumers increasingly taking an interest in preventive approaches and seeking to manage their own health through science-backed products and services. Driven by the emergence of high profile companies like Function, the US consumer health market has seen substantial growth but naturalX believes the sector remains fragmented and underfunded in Europe.
The fund was founded by Marvin Amberg, a German entrepreneur with experience in both consumer and health startups, in collaboration with plant-based pharmaceutical company Schwabe Group.
“The consumer health space has been overlooked by investors,” said Amberg. “We see an inflection point in Europe now, as consumers are finally taking more charge of their own health. Startups in the space need a partner with a shared vision.”
Despite the emergence of success stories like Oura and Neko Health, the firm says that European startups in the consumer health space often struggle to secure the investment needed to scale. naturalX aims to address this gap by providing targeted funding and strategic support.
“We analyzed the US health market and in many successful startups, the consumer is already at the center,” added Amberg. “Our thesis is that this is just the beginning, and the European market will develop in a similar pattern.”
With an investment philosophy that defines consumer health as the intersection of wellness and medicine, naturalX is particularly interested in solutions targeting proactive health areas such as sleep, gut health, prevention and longevity. The fund’s primary focus is on Series-A investments, although it will also consider late Seed and Series-B rounds, offering initial investments ranging from €3-5 million and up to €10 million per company.
Over the past 18 months, naturalX has already made investments in companies including mybacs, Flow Neuroscience, Kyan Health and Meela, as well as in other healthcare-focused venture capital funds to strengthen the ecosystem around its investment thesis. The fund says it is now actively expanding its investment team and seeking partnerships with European entrepreneurs who share its vision of reshaping consumer health.
